Companies / MVP

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

ASX:MVPPharmaceuticals, Biotechnology & Life Sciences
112.7M shares on issueASX (delayed) · as of 28 July 2026$0.48price · delayed$56.3Mmarket cap · indicative
A
Dilution grade

Share count grew 8% in 24 months

Cash runway15.6 quarters of funding
Share-count growth (24m)7.9%
Raise cadence (24m)0 cash raises
Options & rights overhang0.0% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED's ordinary share count changed 7.9% between August 2024 and August 2024, to 113M shares. The company did not raise capital by placement, rights issue or SPP in the 24-month window. No proposed securities issues (Appendix 3B) are pending. At the June 2026 quarter the company reported A$22.2M in available cash, equal to 15.6 quarters of funding at its recent spending rate.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
0.0%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
15.6 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 112.7M per ASX (delayed) (28 July 2026).
112.2M112.7M113.1MDec 24Sept 25July 26

Cash runway

—
Cover not computed for the latest quarter.
$22.2M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
14 May 20263H · cancellationMVP : ORDINARY FULLY PAID112.7MAppendix 3H
20 Apr 20263H · cancellationMVP : ORDINARY FULLY PAID112.7MAppendix 3H
2 June 20253G · unquotedORDINARY FULLY PAID112.7MAppendix 3G
2 Oct 20243H · cancellationMVP : ORDINARY FULLY PAID112.7MAppendix 3H
27 Aug 20242A · quoted issueMVP : ORDINARY FULLY PAID112.7MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

No options or rights over unissued shares on record.

Director dealings

DateDirectorTypeSharesOptionsValueSource
30 Oct 2025Russell BasserBuy40k—$28k3Y notice
30 Sept 2025Mark FladrichBuy63k——3Y notice
22 Sept 2025Paul TownsendBuy25k——3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

23 July 2026$PAppendix 4C and Quarterly Activity Report 30 June 2026
1 July 2026Change in substantial holding
3 June 2026Becoming a substantial holder
2 June 2026Change in substantial holding
14 May 2026Notification of cessation of securities - MVP
23 Apr 2026$PAppendix 4C and Quarterly Activity Report 31 March 2026
20 Apr 2026Notification of cessation of securities - MVP
16 Apr 2026Change in substantial holding
18 Feb 2026$PFY26 Half Year Announcement
18 Feb 2026$PFY26 Half Year Presentation
18 Feb 2026$PFY26 Half Year Report (including Appendix 4D)
16 Feb 2026FY26 Half Year Announcement Details
29 Jan 2026$PAppendix 4C and Quarterly Activity Report 31 December 2025
3 Nov 2025Change of Director's Interest Notice - R Basser
13 Oct 20252025 Annual General Meeting Webcast recording
10 Oct 2025Results of 2025 Annual General Meeting
9 Oct 20252025 Annual General Meeting Presentation
9 Oct 20252025 Annual General Meeting Chair and CEO addresses
9 Oct 2025$PAppendix 4C and Quarterly Activity Report 30 September2025
30 Sept 2025Change of Director's Interest Notice - M Fladrich

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.